Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 14 of 14

TitleReference numberPublishedLast updated
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
VA ECMO for severe acute heart failure in adultsIPG807
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestIPG808
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Head injuryQS74
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessmentHTG760
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100

Results per page

  1. 10
  2. 25
  3. 50
  4. All